Free Trial

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$44.32 +2.79 (+6.72%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Key Stats

Today's Range
$42.50
$45.67
50-Day Range
$41.40
$66.18
52-Week Range
$13.47
$72.98
Volume
25.37 million shs
Average Volume
33.15 million shs
Market Capitalization
$10.02 billion
P/E Ratio
55.40
Dividend Yield
N/A
Price Target
$38.92
Consensus Rating
Reduce

Company Overview

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 66% of companies evaluated by MarketBeat, and ranked 426th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 2 buy ratings, 8 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is 56.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is 56.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.42.

  • Price to Earnings Growth Ratio

    Hims & Hers Health has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 18.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    31.07% of the outstanding shares of Hims & Hers Health have been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 8.72%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    31.07% of the outstanding shares of Hims & Hers Health have been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 8.72%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Hims & Hers Health has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Hims & Hers Health this week, compared to 46 articles on an average week.
  • Search Interest

    172 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.
  • MarketBeat Follows

    51 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 55% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,753,898.00 in company stock.

  • Percentage Held by Insiders

    17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Stock News Headlines

One tiny company just cracked Google’s $19B problem
For decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar.tc pixel
GLP-1 related drugs newspaper headlines with hand and magnifying glass
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets
The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.
Insider Trading
Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4 (HIMS)
A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.
Hims & Hers Health: Still Undervalued
Hims & Hers: The Dominant Health Platform Of The Future
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $24.18 at the beginning of 2025. Since then, HIMS shares have increased by 86.1% and is now trading at $45.0110.

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings data on Monday, August, 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by $0.01. The firm's revenue for the quarter was up 72.6% compared to the same quarter last year.
Read the conference call transcript
.

Hims & Hers Health's top institutional shareholders include State Street Corp (3.15%), Geode Capital Management LLC (2.12%), Jane Street Group LLC and Invesco Ltd. (1.14%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Michael Chi, Patrick Harrison Carroll, Soleil Boughton, Oluyemi Okupe, Christopher D Payne, Andrew Dudum, Christiane Pendarvis, Anja Manuel, Irene Becklund, Irene Becklund and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/04/2025
Today
9/03/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Healthcare
Current Symbol
NYSE:HIMS
CIK
1773751
Fax
N/A
Employees
1,637
Year Founded
N/A

Price Target and Rating

High Price Target
$68.00
Low Price Target
$26.00
Potential Upside/Downside
-14.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.92
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.80
Trailing P/E Ratio
56.88
Forward P/E Ratio
156.93
P/E Growth
2.86
Net Income
$126.04 million
Net Margins
9.63%
Pretax Margin
6.91%
Return on Equity
26.26%
Return on Assets
13.06%

Debt

Debt-to-Equity Ratio
1.72
Current Ratio
4.98
Quick Ratio
4.46

Sales & Book Value

Annual Sales
$1.48 billion
Price / Sales
6.97
Cash Flow
$0.38 per share
Price / Cash Flow
120.26
Book Value
$2.49 per share
Price / Book
18.28

Miscellaneous

Outstanding Shares
226,020,000
Free Float
185,992,000
Market Cap
$10.29 billion
Optionable
Optionable
Beta
2.14

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSE:HIMS) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners